Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Asthma-III: Symptoms and Complications

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Current perspectives on β<sub>2</sub>-adrenergic receptor agonists in asthma: navigating from track to track within GINA recommendations.

Expert opinion on pharmacotherapy·2026

Same author

Upper and lower airway crosstalk in acute exacerbations of COPD: a clinical and biological overview.

Expert review of respiratory medicine·2026

Same author

How many blood eosinophil measurements are needed to identify COPD patients eligible for biologic therapy? A multi-source decision analysis simulation.

European journal of internal medicine·2026

Same author

Mucus plugs in COPD and cardiovascular mortality: An emerging risk pathway and the therapeutic potential of mucolytic strategies.

Respiratory medicine·2026

Same author

Impact of IL-4/IL-13 Blockade with Dupilumab on the Microbiome in Type 2 Inflammatory Diseases: A Systematic Review.

Current allergy and asthma reports·2026

Same author

Mucus Plugging as a Treatable Trait Across the Asthma-COPD Spectrum: The Role of Type 2 Cytokine Blockade and Quantitative Imaging.

Biomedicines·2026

Search research articles

Related Experiment Video

Updated: Nov 26, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Prospects for severe asthma treatment.

Luigino Calzetta¹, Maria Gabriella Matera², Angelo Coppola³

¹Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.

Current Opinion in Pharmacology

|December 14, 2020

Summary

Biological drugs improve severe asthma control by targeting type 2 immunity. Further research is needed for biomarkers and treatments for non-responsive patients.

Keywords:

Biologics Biomarkers Inflammation Monoclonal antibodies Severe asthma

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Acupuncture in a Rat Model of Asthma

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Related Experiment Videos

Last Updated: Nov 26, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Acupuncture in a Rat Model of Asthma

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Area of Science:

Immunology
Pulmonology
Pharmacology

Background:

Biological drugs target type 2 immunity mediators for severe uncontrolled asthma.
These therapies reduce exacerbations, improve symptom control, and decrease corticosteroid use.

Purpose of the Study:

Evaluate current biological drugs for severe asthma.
Identify biomarkers for diagnosis, prognosis, and treatment response.
Discover new molecular targets for non-responsive patients.

Main Methods:

Review of current biological therapies for severe asthma.
Analysis of existing literature on biomarkers.
Exploration of novel therapeutic targets in asthma pathophysiology.

Main Results:

Biological drugs are effective but lack head-to-head comparisons.
Specific biomarkers for diagnosis and treatment response are needed.
New targets are required for patients unresponsive to current biologics.

Conclusions:

Biological therapies have advanced asthma management.
Further research should focus on comparative studies, biomarkers, and novel therapeutic strategies.
Addressing non-type 2 inflammatory pathways is crucial for treatment-resistant asthma.